Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022GlobeNewsWire • 07/21/22
Gritstone bio: Investing In A Premium mRNA Technology At A Discounted ValuationSeeking Alpha • 06/14/22
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature CommunicationsGlobeNewsWire • 06/10/22
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/22
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and DeliveryGlobeNewsWire • 04/12/22
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 03/10/22
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual MeetingGlobeNewsWire • 03/08/22
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)GlobeNewsWire • 01/13/22
Gritstone Says Omicron Mutations Minimally Impact T-Cell Epitope Sequences In Its COVID-19 VaccinesBenzinga • 11/29/21
Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 11/28/21
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2GlobeNewsWire • 11/10/21